Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2013 1
2017 1
2018 1
2019 1
2020 1
2021 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, García-Gutiérrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bédoucha V, Hochhaus A. Réa D, et al. Among authors: lomaia e. Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984. Blood. 2021. PMID: 34407542 Free PMC article. Clinical Trial.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Mauro MJ. Hochhaus A, et al. Among authors: lomaia e. Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717654 Free PMC article. Clinical Trial.
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, Chuah C, Sacha T, Lipton JH, Schiffer CA, McCloskey J, Hochhaus A, Rousselot P, Rosti G, de Lavallade H, Turkina A, Rojas C, Arthur CK, Maness L, Talpaz M, Mauro M, Hall T, Lu V, Srivastava S, Deininger M. Cortes J, et al. Among authors: lomaia e. Blood. 2021 Nov 25;138(21):2042-2050. doi: 10.1182/blood.2021012082. Blood. 2021. PMID: 34407543 Free PMC article. Clinical Trial.
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
Gupta V, Griesshammer M, Martino B, Foltz L, Tavares R, Al-Ali HK, Giraldo P, Guglielmelli P, Lomaia E, Bouard C, Paley C, Tiwari R, Zor E, Raanani P. Gupta V, et al. Among authors: lomaia e. Leuk Lymphoma. 2021 Apr;62(4):918-926. doi: 10.1080/10428194.2020.1845334. Epub 2020 Nov 19. Leuk Lymphoma. 2021. PMID: 33210570 Clinical Trial.
Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL, Subortseva IN, Gilyazitdinova EA, Koloshejnova TI, Pustovaya EI, Egorova EK, Kovrigina AM, Sudarikov AB, Abdullaev AO, Lomaia EG, Siordiya NT, Zaritskey AY, Savchenko VG. Melikyan AL, et al. Among authors: lomaia eg. Ter Arkh. 2018 Aug 17;90(7):23-29. doi: 10.26442/terarkh201890723-29. Ter Arkh. 2018. PMID: 30701919 Clinical Trial.
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M. Brioli A, et al. Among authors: lomaia e. Leukemia. 2024 May;38(5):1072-1080. doi: 10.1038/s41375-024-02204-y. Epub 2024 Mar 28. Leukemia. 2024. PMID: 38548962 Free PMC article.
Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience.
Chitanava T, Matvienko I, Shuvaev V, Voloshin S, Martynkevich I, Vlasova Y, Efremova E, Mileeva E, Pirkhalo A, Makarova T, Vlasik R, Karyagina E, Il Ina N, Medvedeva N, Dorofeeva N, Shneider T, Siordiya N, Kulemina O, Sbityakova E, Lazorko N, Alexeeva J, Motorin D, Morozova E, Lomaia E. Chitanava T, et al. Among authors: lomaia e. Front Oncol. 2023 Mar 16;13:1138683. doi: 10.3389/fonc.2023.1138683. eCollection 2023. Front Oncol. 2023. PMID: 37007128 Free PMC article.
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
Lauseker M, Bachl K, Turkina A, Faber E, Prejzner W, Olsson-Strömberg U, Baccarani M, Lomaia E, Zackova D, Ossenkoppele G, Griskevicius L, Schubert-Fritschle G, Sacha T, Heibl S, Koskenvesa P, Bogdanovic A, Clark RE, Guilhot J, Hoffmann VS, Hasford J, Hochhaus A, Pfirrmann M. Lauseker M, et al. Among authors: lomaia e. Am J Hematol. 2019 Nov;94(11):1236-1243. doi: 10.1002/ajh.25628. Epub 2019 Sep 14. Am J Hematol. 2019. PMID: 31456269 Free article.
13 results